United Therapeutics Corp Stock Prediction
AI-powered sentiment analysis and prediction trends for UTHR, updated each market day.
UTHR AI Sentiment
AI sees no strong directional signal for United Therapeutics Corp stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About United Therapeutics Corp
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Sector
Exchange
Market Cap
$25,190,839,082
Cap Tier
Employees
1,400
Headquarters
SILVER SPRING, MD
Listed Since
June 17, 1999
Website
UTHR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
UTHR Volatility
United Therapeutics Corp has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
